Forward looking statements

To the extent that this presentation contains any forecasts, projections or other forward looking statements, they are based upon current expectations and are subject to uncertainty and contingencies, many of which are outside the control of CathRx. Actual performance, events, results or outcomes may differ for a variety of reasons. Furthermore, the assumptions underlying the forward looking statements could prove inaccurate or incorrect. Therefore, there can be no assurance actual results, performance or achievements will be as stated. The reliance that a recipient of this presentation places on any statement, forecast, protection or assumption is a matter for their own commercial judgment. This presentation has been prepared in good faith and with due care. However, none of CathRx or its directors, employees or advisers warrant or represent the accuracy or completeness of the information contained in this presentation.
### Background

<table>
<thead>
<tr>
<th>Proposed Structural Changes</th>
<th>CathRx Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CXD Delisting</strong></td>
<td>• Seek to negotiate strategic transaction/s with organisations who have regulatory and marketing expertise to supply and market CXD modular SUD cardiac catheter suite in their respective markets</td>
</tr>
<tr>
<td>▪ CathRx has applied to the ASX for CathRx to be delisted</td>
<td></td>
</tr>
<tr>
<td>▪ An Unlisted company structure will reduce ongoing costs and maximise flexibility in negotiating corporate agreements</td>
<td></td>
</tr>
<tr>
<td>▪ The proposed delisting will require shareholder approval</td>
<td></td>
</tr>
<tr>
<td><strong>Capital Raising</strong></td>
<td>• CathRx to be a specialist catheter manufacturer/technology design house focused on design and development of a proprietary suite of modular SUD cardiac catheter products</td>
</tr>
<tr>
<td>▪ CathRx had negotiated an underwriting for a $5M shareholder entitlement offer at $0.01 per share, however, in recent trades the Company’s market price fell to $0.004, a price the board considers overly dilutive for a capital raising.</td>
<td></td>
</tr>
<tr>
<td>▪ The company now intends to raise new capital to fund operating activities post delisting the company</td>
<td></td>
</tr>
<tr>
<td><strong>Module manufacturing contracted through a third party specialist manufacturer in Malaysia</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CathRx revenue to be derived from revenue linked licensing fees from each regional licensee</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Continue to develop and extend the CXD cardiac catheter suite, including the development of products to target the untapped Advanced AF market</strong></td>
<td></td>
</tr>
</tbody>
</table>
CathRx targets global cardiac catheter markets

2012 Estimated Target Global Cardiac Catheter Markets (US$ Millions)*

- Europe, $300m, 25%
- North America, $590m, 49%
- Japan, $150m, 12%
- ROW, $170m, 14%

* Management estimates from available data. Includes estimates for the fixed curve, deflectable diagnostics, loop diagnostics, standard ablation, irrigated ablation and specialty ablation markets.

* European estimates converted to US$ at an assumed exchange rate of US$1.00 : €0.80
CathRx’s patented innovation:
Modular SUD Catheters

1. Traditionally Cardiac Catheters sold by original device manufacturers (OEM’s) as single-use devices (SUD’s)

2. Reprocessing has now achieved significant market share by enabling single-use devices to be re-used after a cleaning, sterilisation and testing process & offering large cost savings to hospitals (US & Germany). However, several countries discourage or ban reprocessing largely due to safety concerns (eg. UK, France)

3. CathRx has designed unique Modular catheters that can deliver cost savings to hospitals without re-using bloodstream contacting components
   - Potential to register as single-use device for each cycle
   - Minimises device cost whilst maintaining high quality & functionality
   - Applicable to all markets

For personal use only
CathRx’s patented ‘Modular SUD’ catheter design

✅ Design catheters in 3 modules - single-use sheath, multiple-use handle & cable
✅ Disposable sheath → no recycling of patient bloodstream contacting modules
✅ ~80% catheter cost engineered into multiple-use high quality non-blood contacting handle and cable
✅ New high quality, low cost single-use products
CathRx product suite to address all major market segments

European Catheter Market
(Estimated Market Segments by Value)

- AblatoRx (Irrigated)
- LineaRx (Irrigated)
- Irrigated/Specialty Ablation 27%
- AblatoRx (Non-Irrigated)
- Standard Ablation 23%
- SensoRx (Fixed)
- Fixed curve diagnostics 14%
- SensoRx (Deflectable)
- Deflectable diagnostics 20%
- CirculaRx (Fixed & Variable)
- Loop diagnostics 16%

Source: Management estimates from available data.
CathRx modular SUD catheter family under development

- SensoRx
  - Fixed Curve SensoRx
  - Deflectable Curve SensoRx
  - Fixed Loop CirculaRx
  - 20E Deflectable curve SensoRx
  - 20E Fixed Loop CirculaRx
- CirculaRx
  - 20E Variable Loop CirculaRx
- AblatoRx
  - Irrigated AblatoRx
**Evolution of Cardiac Catheter Supply Models**

**Illustrative Example: Deflectable 10E**
- OEM deflectable 10E price $470
- Hospital purchases 1 new deca for every 4 uses
- Reprocessors charge $235 per reuse
- Set CathRx price per use @ $250 per use

<table>
<thead>
<tr>
<th>USE #</th>
<th>Original Model</th>
<th>OEM + Reprocessing Model</th>
<th>CathRx Model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OEM* Hospital cost</td>
<td>OEM Reprocessor** Hospital cost</td>
<td>Fee per use Hospital Cost</td>
</tr>
<tr>
<td>1</td>
<td>$470 $470</td>
<td>$470 - $250 $290</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>$470 $470</td>
<td>- $235 $235</td>
<td>$250 $290</td>
</tr>
<tr>
<td>3</td>
<td>$470 $470</td>
<td>- $235 $235</td>
<td>$250 $290</td>
</tr>
<tr>
<td>4</td>
<td>$470 $470</td>
<td>- $235 $235</td>
<td>$250 $290</td>
</tr>
<tr>
<td>5</td>
<td>$470 $470</td>
<td>$470 - $470</td>
<td>$250 $290</td>
</tr>
<tr>
<td>6</td>
<td>$470 $470</td>
<td>- $235 $235</td>
<td>$250 $290</td>
</tr>
<tr>
<td>7</td>
<td>$470 $470</td>
<td>- $235 $235</td>
<td>$250 $290</td>
</tr>
<tr>
<td>8</td>
<td>$470 $470</td>
<td>- $235 $235</td>
<td>$250 $290</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$3,760 $3,760</strong></td>
<td><strong>$940 $1,410 $2,350</strong></td>
<td><strong>$2,000 $2,000</strong></td>
</tr>
</tbody>
</table>

* Estimated average price of a deflectable deca in the United States
** Estimated fees for reprocessing deflectable deca products (from 2011 Ascent brochure)
Next Steps

- Begin discussions with global original manufacturers (OEM’s)
  - OEM’s are predominately based in the US
  - OEM’s have global operations and may be interested in global transaction/s
  - Planning to initiate discussions in November
- Important for the delisting to be complete to maximise flexibility in negotiations

2012 Estimated Cardiac Catheter Markets (US$)

- North America: $590m, 49%
- Europe: $300m, 25%
- ROW: $170m, 14%
- Japan: $150m, 12%
Large Market Growth Potential

* Current AF Market estimate is CathRx’s estimated value of the cardiac catheter market for AF procedures only. The potential AF Market is based on assuming cardiac catheter ablation penetration increases from ~2-3% to 50% of AF patients.
Questions?